Afatinib

Red

Brand Name(s):Giotrif

Indication:Lung cancer non-small cell (NSCLC) with activating EGFR mutation(s)-for EGFR TKI-naïve adult patients

Rationale:1,2

Considered:Sep-13

Review Date:May-24

Comments:
Afatinib is recommended as an option, within its marketing authorisation, for
treating adults with locally advanced or metastatic non-small-cell lung cancer
only if:
the tumour tests positive for the epidermal growth factor receptor tyrosine kinase
(EGFR-TK) mutation and
the person has not previously had an EGFR-TK inhibitor and
the manufacturer provides afatinib with the discount agreed in the patient access
scheme.